GALECTIN THERAPEUTICS INC

Uihlein’s record‑setting buy of 34 million Galectin shares signals insider confidence in its biotech pipeline, offering a rare upside chance amid volatility.

GALECTIN THERAPEUTICS insider trading: CMO’s Rule 10b5‑1 buys and sells reveal confidence in its fibrotic and cancer pipeline, while offering insight into future shareholder value.

Insider buying at Galectin Therapeutics shows long‑term confidence in its fibrotic and cancer drug pipeline, even amid volatile social‑media buzz.

Galectin Therapeutics insider buys low, sells high—Jamil Khurram’s 10b5‑1 plan signals confidence in the company’s fibrotic & cancer pipeline and upcoming clinical milestones.

Insider buying by Galectin Therapeutics’ CMO signals confidence in belapectin and a potential upside, sparking investor interest and a modest weekly gain.

CEO Lewis Joel sells 56k Galectin Therapeutics shares—what the move means for insider confidence, liquidity, and the company’s future.